Bausch Health Companies Inc (BHC)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $3.13B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bausch Health Companies Inc (BHC) Financials: Revenue, Profit and Cash Flow
Bausch Health Companies reported revenue of $10.27B for the fiscal year ended Dec 31, 2025, up 6.7% from the year before. That year, net income was $120.00M with a net margin of 1.2%, operating cash flow was $1.40B and free cash flow was $1.00B. The quarter ended Sep 30, 2026 had revenue of $2.94B and net income of $446.00M.
Revenue and Margins
The operating margin was 17.7% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $9.67B, a compound annual rate of 0.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $10.27B | +6.7% | 70.7% | 17.7% | 1.2% |
| Dec 2024 | $9.63B | +9.9% | 71.1% | 16.1% | -0.7% |
| Dec 2023 | $8.76B | +7.8% | 70.8% | 11.0% | -7.0% |
| Dec 2022 | $8.12B | -3.7% | 70.9% | 5.6% | -2.6% |
| Dec 2021 | $8.43B | N/A | 71.6% | 5.3% | -11.1% |
| Dec 2020 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2019 | $8.60B | +2.6% | 72.7% | -2.4% | -20.7% |
| Dec 2018 | $8.38B | -3.9% | 71.9% | -28.4% | -49.5% |
| Dec 2017 | $8.72B | -9.8% | 70.8% | 1.2% | 27.6% |
| Dec 2016 | $9.67B | N/A | 73.0% | -5.9% | -24.9% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income rose 146.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.27B | $9.63B | $8.76B | $8.12B | $8.43B | $0 | $8.60B | $8.38B | $8.72B | $9.67B |
| Cost of revenue | $3.01B | $2.78B | $2.56B | $2.36B | $2.39B | $0 | $2.35B | $2.35B | $2.55B | $2.61B |
| Gross profit | $7.25B | $6.84B | $6.20B | $5.76B | $6.04B | $0 | $6.25B | $6.03B | $6.18B | $7.06B |
| Research and development | $629.00M | $616.00M | $604.00M | $529.00M | $465.00M | $452.00M | $471.00M | $413.00M | $361.00M | $455.00M |
| Operating income | $1.81B | $1.55B | $963.00M | $454.00M | $450.00M | $676.00M | -$203.00M | -$2.38B | $102.00M | -$566.00M |
| Net income | $120.00M | -$72.00M | -$611.00M | -$212.00M | -$937.00M | -$559.00M | -$1.78B | -$4.14B | $2.40B | -$2.41B |
| EBITDA | $3.13B | $2.90B | $2.26B | $1.94B | $2.06B | $2.53B | $1.94B | $537.00M | $3.22B | $2.38B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.94B | $2.85B | $2.52B | $2.80B | $2.68B | $2.53B | $2.26B | $2.56B | $2.51B | $2.40B | $2.15B | $2.41B |
| Gross profit | $2.21B | $2.08B | $1.79B | $2.00B | $1.93B | $1.77B | $1.56B | $1.83B | $1.81B | $1.68B | $1.51B | $1.70B |
| Operating income | $983.00M | $740.00M | -$950.00M | $474.00M | $619.00M | $444.00M | $276.00M | $558.00M | $318.00M | $389.00M | $281.00M | $362.00M |
| Net income | $446.00M | $260.00M | -$1.43B | -$103.00M | $181.00M | $128.00M | -$86.00M | $98.00M | -$92.00M | -$1.00M | -$77.00M | -$47.00M |
Balance Sheet
As of Dec 2025, total debt of $20.82B exceeded cash and equivalents by $19.51B. Shareholder equity was negative, at -$554.00M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $26.37B | $26.52B | $27.35B | $25.69B | $29.20B | $31.20B | $33.86B | $32.49B | $37.50B | $43.53B |
| Current assets | $6.16B | $5.77B | $5.60B | $4.25B | $5.61B | $5.34B | $6.97B | $4.21B | $4.75B | $5.08B |
| Cash and equivalents | $1.31B | $1.18B | $947.00M | $564.00M | $582.00M | $605.00M | $3.24B | $721.00M | $720.00M | $542.00M |
| Total liabilities | $25.99B | $26.84B | $27.43B | $25.43B | $29.24B | $30.59B | $32.73B | $29.68B | $31.55B | $40.27B |
| Short-term debt | $225.00M | $2.67B | $450.00M | $432.00M | $0 | $52.00M | $1.23B | $228.00M | $209.00M | $1.00M |
| Long-term debt | $20.59B | $18.94B | $21.94B | $20.33B | $22.65B | $23.93B | $24.66B | $24.08B | $25.23B | $29.84B |
| Shareholder equity | -$554.00M | -$1.28B | -$1.02B | -$692.00M | -$106.00M | $535.00M | $1.06B | $2.73B | $5.85B | $3.15B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $25.48B | $24.79B | $24.50B | $26.32B | $26.82B | $27.27B | $26.42B | $26.52B | $26.54B | $26.50B | $26.91B | $27.35B |
| Total liabilities | $25.82B | $25.60B | $25.58B | $25.94B | $26.47B | $27.12B | $26.66B | $26.84B | $26.78B | $26.72B | $27.09B | $27.43B |
| Cash and equivalents | $2.48B | $1.82B | $1.30B | $1.32B | $1.31B | $1.73B | $1.13B | $1.18B | $719.00M | $595.00M | $733.00M | $947.00M |
| Shareholder equity | -$1.33B | -$1.77B | -$2.06B | -$552.99M | -$565.00M | -$764.00M | -$1.18B | -$1.28B | -$1.17B | -$1.18B | -$1.11B | -$1.02B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 71.4% of operating cash flow.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.40B | $1.60B | $1.03B | -$728.00M | $1.43B | $1.11B | $1.50B | $1.50B | $2.29B | $2.09B |
| Capital expenditures | $397.00M | $337.00M | $215.00M | $218.00M | $269.00M | $302.00M | $270.00M | $157.00M | $171.00M | $235.00M |
| Free cash flow | $1.00B | $1.26B | $817.00M | -$946.00M | $1.16B | $809.00M | $1.23B | $1.34B | $2.12B | $1.85B |
| Dividends paid | N/A | N/A | N/A | $31.00M | N/A | N/A | N/A | N/A | $18.00M | $9.00M |
| Investing cash flow | -$595.00M | -$454.00M | -$2.15B | -$303.00M | $409.00M | -$261.00M | -$419.00M | -$196.00M | $2.89B | -$125.00M |
| Financing cash flow | -$742.00M | -$868.00M | $1.48B | -$474.00M | -$1.51B | -$2.29B | $1.44B | -$1.35B | -$4.96B | -$1.96B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $814.00M | $670.00M | $230.00M | $495.00M | $405.00M | $289.00M | $211.00M | $601.00M | $405.00M | $380.00M | $211.00M | $390.00M |
| Capital expenditures | $66.00M | $77.00M | $109.00M | $92.00M | $91.00M | $99.00M | $115.00M | $106.00M | $71.00M | $78.00M | $82.00M | $98.00M |
| Free cash flow | $748.00M | $593.00M | $121.00M | $403.00M | $314.00M | $190.00M | $96.00M | $495.00M | $334.00M | $302.00M | $129.00M | $292.00M |
Frequently Asked Questions About BHC
What is Bausch Health Companies' annual revenue?
Bausch Health Companies reported revenue of $10.27B for the fiscal year ended Dec 31, 2025.
How fast is Bausch Health Companies' revenue growing?
Revenue was up 6.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 8.1%.
Is Bausch Health Companies profitable?
Yes. Bausch Health Companies reported net income of $120.00M for the fiscal year ended Dec 31, 2025, with a net margin of 1.2%.
How much free cash flow does BHC generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.40B minus capital expenditures of $397.00M produced free cash flow of $1.00B.
How much debt does Bausch Health Companies have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $20.59B, short-term debt of $225.00M and cash and equivalents of $1.31B.
BHC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors